Arzneimittelforschung 2009; 59(2): 96-103
DOI: 10.1055/s-0031-1296370
Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Synthesis, Anticancer and Radioprotective Activities of Some New Pyrazolo[3,4-d]pyrimidines Containing Amino Acid Moieties

Mostafa M Ghorab
1   Department of Drug Radiation Research, National Centre for Radiation Research and Technology, Atomic Energy Authority, Nasr City, Cairo, (Egypt)
,
Fatma A Ragab
2   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, (Egypt)
,
Eman Noaman
3   Department of Radiation Biology, National Centre for Radiation Research and Technology, Atomic Energy Authority, Nasr City, Cairo, (Egypt)
,
Helmy I. Heiba
1   Department of Drug Radiation Research, National Centre for Radiation Research and Technology, Atomic Energy Authority, Nasr City, Cairo, (Egypt)
,
Sarah A. Aboulmagd
1   Department of Drug Radiation Research, National Centre for Radiation Research and Technology, Atomic Energy Authority, Nasr City, Cairo, (Egypt)
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
14. Dezember 2011 (online)

Preview

Abstract

Various isomeric structural purine analogues possessing the pyrazolo[3,4-d]pyrimidine nucleus bearing amino acid moieties have been synthesized. The structures of the synthesized compounds were elucidated by spectral data. Preliminary testing for in vitro anticancer activity of the synthesized compounds against Ehrlich ascites carcinoma cells was carried out.

2-(1-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-propanoic acid (3b), 4-methyl-2-(1-phenyl-1H-pyrazolo[3,4-d] pyrimidin-4-ylamino)-pentanoic acid (3d), 4-methylthio-2-( 1-phenyl- 1H-pyra-zolo[3,4-d] pyrimidin-4-ylamino)-butanoic acid (3e) and phenyl-2-(1-phenyl-1H-pyrazolo[3,4-d] pyrimidin-4-ylamino)-propanoic acid (3f) were the most active compounds. Moreover, compounds 3e and 1-( 1-phenyl-1H-pyrazolo[3,4-d] pyrimidin-4-yl)-pyrrolidine-2-carboxylic acid (4) exhibited significant in vivo radioprotective activity.